Apolipoprotein E driven therapeutics for Alzheimer’s disease

Phase 1

• Conditions: Alzheimer's Disease; Neurological - Alzheimer's disease

• Registration Number: ACTRN12613000465752
• Lead Sponsor: uclear Medicine and Centre for PET Research Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Completion of the standard evaluation and fulfillment of the specific diagnostic criteria for very early Alzheimer's Disaease and mild Alzheimer's Disease. Also to be fluent in English; Age >50; >7 years of education; adequate visual and auditory acuity to complete neuropsychological testing;to have a reliable caregiver who is able to provide accurate information about the patient’s symptoms;

Exclusion Criteria

A negative brain PET scan;a lifetime history of schizophrenia, schizoaffective disorder, or treatment with ECT;recent history of drug or alcohol abuse/dependence;
any significant disease or unstable medical condition that in the opinion of the investigators, could affect drug levels or neuropsychological testing.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Brain ABeta burden as measured by NAV4694-PET scan[A baseline scan is taken and then at the completion of 30 days of treatment of bexarotene]

Secondary Outcome Measures

Name	Time	Method
Change in cognition. <br>Cognition is assessed through neuropsychological assessments where memory and attention tasks are completed. Assessments take 1-2 hours.<br>[The assessments will occur at screening, the last week of treatment then at 3 months post treatment. ]